ePT--the Electronic Newsletter of Pharmaceutical Technology, Apr 26, 2012 - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

ePT--the Electronic Newsletter of Pharmaceutical Technology, Apr 26, 2012
News
FDA Details Strategies for Addressing Globalization
By Patricia Van Arnum
A new report by FDA details the strategies, programs, and other activities the agency is using to address the rise of imported pharmaceutical products and APIs.
GSK Divests OTC Brands Worth $264.7 Million
By Stephanie Sutton
GlaxoSmithKline has reached an agreement to divest certain over-the-counter brands in selected territories to South Africa's Aspen Pharmacare Holdings for approximately $264.7 million.
FDA Reports Improvement in Postmarket Drug Oversight
By Susan Haigney
FDA highlights success of CDER's drug-monitoring program.
Merck KGaA Announces Job Cuts
By Stephanie Sutton
Merck KGaA has revealed further details about its previously announced restructuring program, including plans to eliminate approximately 580 jobs.
EC Offers Cash Prize for Vaccine Stability
By Stephanie Sutton
The European Commission is offering a EUR 2-million ($2.64 million) inducement prize to encourage innovation in the area of cold-chain logistics and vaccine stability.
Week of Apr. 23, 2012: AstraZeneca to Acquire Ardea Biosciences; Pfizer to Divest Nutrition Business to Nestlé; and More
AstraZeneca to Acquire Ardea Biosciences; Pfizer to Divest Nutrition Business to Nestlé; and More.

ADVERTISEMENT

LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
Which of the following business challenge poses the greatest threat to your company?
Building a sustainable pipeline of products
Attracting a skilled workforce
Obtaining/maintaining adequate financing
Regulatory compliance
Building a sustainable pipeline of products
26%
Attracting a skilled workforce
29%
Obtaining/maintaining adequate financing
14%
Regulatory compliance
31%
View Results
Eric Langer Outsourcing Outlook Eric LangerBiopharma Outsourcing Activities Update
Cynthia Challener, PhD Ingredients Insider Cynthia Challener, PhDAppropriate Process Design Critical for Commercial Manufacture of Highly Potent APIs
Jill Wechsler Regulatory Watch Jill Wechsler FDA and Manufacturers Seek a More Secure Drug Supply Chain
Sean Milmo European Regulatory WatchSean MilmoQuality by Design?Bridging the Gap between Concept and Implementation
Click here